Chloronous

Chloronous is a biotechnology company focused on developing novel therapeutic agents that target the hypoxia-inducible factor (HIF) pathway. The company's research centers on small molecule inhibitors designed to modulate cellular responses to low oxygen levels, which are critical in the progression of various cancers and vascular diseases. By targeting HIF-1 alpha and its downstream effectors like VEGF, Chloronous aims to disrupt tumor angiogenesis and metabolic adaptation. Their current pipeline is in the pre-clinical stage, with a primary focus on oncology and ophthalmology indications. The company leverages its expertise in medicinal chemistry to optimize lead compounds for improved efficacy and safety profiles.